Emerging Markets Earnings Roundup: Astra Zeneca and Teva (Part 6)
This article was originally published in PharmAsia News
AstraZeneca reports 21% growth in China, representing $72 million of the $154 million sales increase in emerging markets; and Teva reports $1.47 billion loss due to at-risk launches.
You may also be interested in...
An appeals court ruling on July 26 favoring a faster route to a generic Copaxone brings to the fore longstanding issues of what its regulatory path might look like and how Teva will cope with the erosion of its top product’s sales.
Teva and Lonza agree to dissolve their four-year-old biosimilars joint venture, created at a time when the biosimilars opportunity seemed huge, if vague. In an otherwise slow deal-making week, next-generation antibody platform company Adimab forged two transforming deals with GSK and Biogen, while Kolltan and the Children’s Hospital of Philadelphia plunged into neuroblastoma.
Affymax and its partner Takeda recalled all of their ESA product after rare but unexplained patient fatalities, leaving both the product’s and the company’s future in limbo. The safety concerns may fuel fears about the unknowns of biologic production.